Tercica’s False Advertising Suit Against Insmed Is Dismissed In California
This article was originally published in The Pink Sheet Daily
Executive Summary
San Francisco federal court finds that Insmed's statements to investors about the safety profile of Tercica's growth hormone Increlex do not constitute false advertising.
You may also be interested in...
Insmed, Tercica Head To Court Over Growth Hormone Patents
A San Francisco federal court denied four of Insmed’s five motions for summary judgment, sending the dispute over iPlex and Increlex to trial in November.
Insmed, Tercica Head To Court Over Growth Hormone Patents
A San Francisco federal court denied four of Insmed’s five motions for summary judgment, sending the dispute over iPlex and Increlex to trial in November.
Insmed Growth Treatment iPlex Enters Market
Mecasermin rinfabate injection will compete with Tercica’s Increlex.